A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6712 participants.

Also called NCT06424288

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 6,712 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06424288
  • EU CT 2023-509706-30-00
  • WHO UTN U1111-1302-4422
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Serbia, Slovenia, South Africa, South Korea, Spain, Taiwan, Türkiye, United Kingdom, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06424288. Randomized; triple masking; primary purpose treatment. Start 2024-06-17 (actual); primary completion 2028-05-22 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Condition
Heart Failure
Intervention (Drug)
vicadrostat
Intervention (Drug)
empagliflozin
Intervention (Drug)
placebo
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct06424288
Content hash
89f25c14d8f5902cd4ce84cb295a6a9975b2e15ba267e404bacabfc7370f9778